Role of RAGE in the Pathogenesis of Neurological Disorders.
10.1007/s12264-022-00878-x
- Author:
Judyta JURANEK
1
;
Konark MUKHERJEE
2
;
Bernard KORDAS
3
;
Michał ZAŁĘCKI
4
;
Agnieszka KORYTKO
3
;
Kamila ZGLEJC-WASZAK
3
;
Jarosław SZUSZKIEWICZ
5
;
Marta BANACH
6
Author Information
1. Department of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury, 10-085, Olsztyn, Poland. judytajuranek@gmail.com.
2. Fralin Biomedical Research Institute at VTC, Virginia Tech, Blacksburg, VA, 24016, USA.
3. Department of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury, 10-085, Olsztyn, Poland.
4. Department of Animal Anatomy, Faculty of Veterinary Medicine, University of Warmia and Mazury, 10-719, Olsztyn, Poland.
5. Department of Materials and Machines Technology, Faculty of Technical Sciences, University of Warmia and Mazury, 10-719, Olsztyn, Poland.
6. Department of Neurology, Collegium Medicum, Jagiellonian University, 31-008, Kraków, Poland. martabanach@yahoo.com.
- Publication Type:Review
- Keywords:
Nervous system;
Neurological disorders;
Receptor for advanced glycation end-products;
Sensorimotor disorders
- MeSH:
Humans;
Ligands;
Nervous System Diseases;
Receptor for Advanced Glycation End Products/metabolism*;
Signal Transduction/physiology*
- From:
Neuroscience Bulletin
2022;38(10):1248-1262
- CountryChina
- Language:English
-
Abstract:
This review reflects upon our own as well as other investigators' studies on the role of receptor for advanced glycation end-products (RAGE), bringing up the latest information on RAGE in physiology and pathology of the nervous system. Over the last ten years, major progress has been made in uncovering many of RAGE-ligand interactions and signaling pathways in nervous tissue; however, the translation of these discoveries into clinical practice has not come to fruition yet. This is likely, in part to be the result of our incomplete understanding of this crucial signaling pathway. Clinical trials examining the therapeutic efficacy of blocking RAGE-external ligand interactions by genetically engineered soluble RAGE or an endogenous RAGE antagonist, has not stood up to its promise; however, other trials with different blocking agents are being considered with hope for therapeutic success in diseases of the nervous system.
